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ABSTRACT:A 2-compartment in vitro eye flowmodel has been developed to estimate ocular drug clearance by the anterior aqueous outflow
pathway. The model is designed to accelerate the development of longer-acting ophthalmic therapeutics. Dye studies show aqueous flow
is necessary for a molecule injected into the vitreous cavity to clear from the model. The clearance times of proteins can be estimated
by collecting the aqueous outflow, which was first conducted with bevacizumab using phosphate-buffered saline in the vitreous cavity. A
simulated vitreous solution was then used and ranibizumab (0.5 mg) displayed a clearance time of 8.1 ± 3.1 days, which is comparable
to that observed in humans. The model can estimate drug release from implants or the dissolution of suspensions as a first step in their
clearance mechanism, which will be the rate-limiting step for the overall resident time of a candidate dosage form in the vitreous. A
suspension of triamcinolone acetonide (Kenalog R©) (4.0 mg) displayed clearance times spanning 26–28 days. These results indicate that the
model can be used to determine in vitro–in vivo correlations in preclinical studies to develop long-lasting therapeutics to treat blinding
diseases at the back of the eye. C© 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the
American Pharmacists Association J Pharm Sci 104:3330–3342, 2015
Keywords: Intraocular fluid flow; in vitro/in vivo correlations (IVIVC); in vitro model; pharmacokinetics; proteins; protein delivery;
intraocular drug suspension; ocular drug delivery; intravitreal injection
INTRODUCTION
Prolonging therapeutic levels of a drug within the vitreous to
treat blinding diseases is one of the most important goals in
ophthalmic drug development. Intravitreal (IVT) injections of
therapeutic proteins and the use of steroid implants in the vitre-
ous are currently the best clinical methods to achieve prolonged
exposure in the back of the eye. With increased life expectancy
and an aging population, more people will require treatment
for longer periods to manage blinding conditions that would
otherwise rapidly progress.
Therapeutic biologics registered for ophthalmic use by IVT
injection comprise a PEGylated-aptamer (Pegaptanib), anti-
body fragment (ranibizumab), and a Fc fusion (alfibercept).1
These medicines bind to VEGF and are administered by IVT
injection every 1–2 months. Although IVT injections are a
costly, invasive procedure that is associated with a low risk
for vision threatening complications,2 many health systems
around the world cannot cope with the increasing demands
for IVT injection of the current anti-VEGF treatments,3,4 even
when administered every 1–2 months. The increased know-
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ledge of the molecular mechanisms involved in blinding ocular
diseases5,6 will continue to drive the development of protein-
based medicines,1 which tend to be potent and have a rapid
onset of action. This will further drive the development7–11 of
longer-lasting IVT injection dosage forms such as implants that
require less frequent administration.
Mass exchange within the eye is dominated by the aqueous
that is secreted into the vitreous from the ciliary body (2.0–
2.5 :L/min).12–16 The vast majority of this aqueous passes the
anterior hyaloid membrane and flows into the front of the eye
(anterior chamber) to then leave the eye via trabecular and
uveoscleral pathways.14–17 Drug elimination from the vitreous
occurs by (1) the aqueous outflow into the anterior chamber and
(2) permeation through the retina via retinal-choroid-sclera
(RCS) pathways.14,18 Therapeutic proteins clear predominantly
through the anterior route because they are high-molecular-
weight, charged molecules.7,19–23
Proteins have longer half-lives (i.e., days to weeks)6,7,20,24,25
in the vitreous than RCS26 permeable molecules (e.g., lipophilic
molecules 500 Da), which generally are a matter of
hours.18,27,28 Reasons for this include (1) lowermolecular weight
permeable molecules diffuse more rapidly in the vitreous than
proteins,18,24,27,28 (2) the surface area of the retina is large com-
pared to the anterior hyaloid membrane, and (3) permeable
molecules can clear via several routes through the RCS (e.g.,
passive diffusion, active transport, binding to melanin, loss to
conjuctival lymphatics and episcleral veins, and metabolism).18
In vitro cell permeation models have been developed to evalu-
ate RCS permeability.29 It is thought that the physicochem-
ical properties of a drug can often be used to predict RCS
permeability.18,29–31
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Little has been reported to develop an in vitro model that
accounts for the aqueous flow32 to estimate clearance times
for molecules that exit the eye predominantly via the anterior
route through the front of the eye. Preclinical pharmacokinetic
research for new ophthalmic preparations is dominated by the
use of animal models. There are a multitude of anatomical dif-
ferences between animal models and human eyes (e.g., aqueous
flow, vitreous volumes, diffusion pathways).28,33–35 Young labor-
atory animals with an intact vitreous structure are often used,
but much is still not understood about the vitreous36 between
species, and animal models do not account for the variabil-
ity and age-related differences of the human vitreous.24,30,37,38
Correlating results from the literature can be complicated be-
cause different experimental techniques are often used to ob-
tain PK data for each species.18 The formation of antidrug an-
tibodies (ADAs) also results in accelerated clearance rates,39
making it impossible to accurately evaluate candidate thera-
peutic proteins.40–43 ADAs can also cause nonspecific inflam-
mation to compromise efficacy. ADA formation is not predic-
tive of the human immunological response and remains an
intractable problem that delays development of humanized pro-
tein therapeutics.44
The use of in vitro models has been important to de-
velop and optimize many dosage forms including pulmonary
(deposition), percutaneous (diffusion), and oral (dissolution)
preparations.45–48 These models are also used to establish
in vitro–in vivo correlations and extrapolations (IVIVC and
IVIVE),49–53 and for quality control.54,55 For longer-acting oph-
thalmic preparations to be developed, preclinical candidates
must display extended half-lives while under the influence of
the aqueous flow within the eye. To address this need, we have
developed an in vitro, two-compartment model scaled to human
dimensions with aqueous flow designed tomimic the total aque-
ousmass transfer through the anterior route. Themodel (called
the PK-Eye) is specifically designed to mimic the intraocular
aqueous outflow to estimate (1) the clearance of therapeutic pro-
teins, (2) the dissolution of drug suspensions, and (3) the release
profiles of implants from the vitreous cavity. The design and
flow properties of the in vitromodel are described and then the
model was used to estimate the intraocular residence times of
ranibizumab, bevacizumab, and triamcinolone acetonide (TA)
suspension, which were compared with published data from in
vivo studies in animals and humans.
MATERIALS AND METHODS
Materials
Kenalog R© (40 mg/mL) was purchased from Squibb. Be-
vacizumab (Avastin R©, 25 mg/mL; Genentech, South San
Francisco, California) and ranibizumab (Lucentis R©, 10 mg/mL;
Genentech, South San Francisco, California) were obtained
from the pooled remaining contents of vials that had been used
clinically. Sodium hyaluronate (solubility: 5.0 mg/mL; 1.8MDa)
was purchased from Aston Chemicals (Aylesbury, UK) and agar
(solubility: 15.0 mg/mL) was obtained from Fluka Analytical
(Gillingham, Dorset, UK). Dye (Coomassie Brilliant Blue, MW
= 825.97 g/mol) was used to validate flow in the model. Visk-
ing dialysis membrane tubing (MWCO of 12–14 kDa) was pur-
chased from Medicell International Ltd. (London, UK). Bovine
serum albumin (BSA) was obtained from Sigma–Aldrich. A 16-
channel Ismatec peristaltic pump (Michael Smith Engineers
Ltd., Woking, Surrey, UK) was used to generate fluid flow into
the PK-Eye. UV measurements were analyzed using Hitachi
U-2800A spectrometer and a Wallac Victor2 1420 plate reader.
HPLC was conducted using a Agilent 1200 series (Agilent,
Wokingham, Berkshire, UK) equipped with Chemstation soft-
ware (Agilent, Wokingham, Berkshire, UK) using a reverse-
phase Synergi Polar-RP Phenomenex 4 :m, 15 cm column.
Methods
Design of the PK-Eye Flow Model
Efforts to develop the model were focused at the outset (1) to
have the anterior and posterior cavities to be a similar size as in
the human eye and (2) to use an aqueous inflow that mimics the
aqueous outflow in humans. The model comprises two plastic
pieces that are secured together with four screws (Fig. 1). The
overall dimensions and volumes of the posterior (4.2 mL) and
anterior (0.2 mL) cavities of the model are comparable to that of
the human eye (Table 1). Several prototypes of the model were
evaluated (Table 2) to best mimic the mass transfer caused by
aqueous outflow. The prototyping efforts listed in Table 2 were
focused to design a model that was both simple to fabricate and
to use. It was found that a single inlet port (1.5 mm ID) with
a flow of 2.0 :L/min15 was the most practical way to mimic
aqueous flow in this model. The aqueous inlet port was placed
in the vitreous cavity near the membrane barrier. An injection
port was placed at the top of the vitreous cavity. A widely avail-
able dialysis membrane (MWCO 12–14 kDa) was fixed between
the posterior and anterior cavities (Fig. 1). This membrane was
used to provide a barrier to the anterior cavity for solubilized
molecules residing in the posterior cavity. For outflow, a single
outlet port in the anterior cavity extended upwards from the
model to provide a small amount of backpressure. This was
used to avoid the formation of air bubbles and to maintain the
total liquid volume within the model.
PK-Eye Dye Validation Studies
The inlet port was connected with tubing (1.5 mm ID) to a
dispensing pump that provided aqueous (phosphate-buffered
saline, PBS) inflow of 2.0 :L/min. Dye (Coomassie Brilliant
Blue) was injected (100 :L, 1.2 mM) into the posterior cavity of
the model in one experiment and then in the anterior cavity in
another experiment to compare the effects of flow at ambient
temperature. For the non-flow experiments, the model was full
of liquid with its ports blocked with parafilm to replicate no
flow. Images were obtained using a digital camera at various
time points to visualize the dye clearance from the model.
Simulated Vitreous and Viscosity Measurements
Agar (0.4 g) and hyaluronic acid (HA) (0.5 g) were each sepa-
rately mixed in 100 mL of stirred hot water.57 The agar solu-
tion was boiled to completely solubilize the agar. After boiling,
the hot agar solution was mixed with HA and stirred to give
a homogenous mixture to which a few drops of 0.02% sodium
azide were added. The solution was left to cool for 24 h to am-
bient temperature (21°C) and formed into a gel-like consis-
tency. Viscosity (n = 3) was measured using an AR 1000-N
Rheolyst Rotational TA rheometer (TA Instruments, Elstree,
UK) at 25°C. Approximately 2.0–3.0 mL of simulated vitreous
was pipetted onto the rheometer plate while avoiding both over
and under filling of the rheometer plate. The rheometer plate
was washed with distilled water before each measurement and
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Figure 1. Top, front and side images of the PK-Eye model used in these studies. The model comprises two plastic pieces that are held together
with four screws with a fitted rubber washer (7) between the two pieces to seal the posterior cavity and to prevent leakage. A membrane (3)
separates the anterior (1) and posterior (2) cavities, which have a volume of 200 :L and 4.2 mL, respectively. The inlet port (4) allows flow
immediately posterior to the membrane (3). The inlet port was connected with plastic tubing (1.5 mm internal diameter) to a 16-channel Ismatec
peristaltic pump to produce a flow rate of 2.0 :L/min of PBS, pH 7.4 with 0.02% sodium azide. Aqueous outflow is collected from the anterior
cavity at a single outlet port (5), which is elevated to about 3.0 cm to provide a small amount of back pressure to maintain a full internal volume
within the model. The inner diameter of the inlet and outlet ports was 1.0–1.5 mm.
Table 1. Average Human Eye Dimensions Versus the Dimensions of
the PK-Eye Model Used in This Study
Average PK-Eye
Dimensions Anatomy Human Eye56 Model
Length (mm) Cornea vertical length 11.0 9.0
Cornea horizontal length 12.0 9.0
Volume (mL) Posterior cavity 3.9–5.0 4.2
Anterior cavity 0.2 0.2
the temperature was kept constant (25°C.) The pseudo-linear
viscoelastic region was determined using an oscillatory stress
sweep over a broad torque range (1–10,000 uN.m). The pseudo-
viscosity profile was obtained using a continuous flow test and
an oscillatory time sweep was used to monitor whether the
properties of the simulated vitreous changed over time.
Protein Clearance Studies
To coat the model with albumin solution, it was filled with
0.1% BSA solution and after securing the injection port, the
model was incubated at 37°C for 12 h (n = 3 for each exper-
iment). The model was then disassembled and washed with
water and refilled with PBS (pH 7.4). To examine the effects
of vitreous viscosity, the simulated vitreous was added to the
posterior cavity by syringe and PBS was added to the ante-
rior cavity through its injection port. Ranibizumab (0.5 mg)
and bevacizumab (1.25 mg) were injected (50 :L) into the cen-
ter of the vitreal cavity and sampling was generally accom-
plished by collection at the outflow port. Samples were stored
at 4°C prior to analysis for protein content by the Bradford
assay.
TA (Kenalog R©) Clearance Studies
The posterior cavity of the model was filled with the appropri-
ate media (PBS, pH 7.4 or simulated viscous vitreous). PBS
(pH 7.4) was then added to the anterior chamber. The aqueous
flow (2.0 :L/min) was started and the model was placed into a
preheated oil bath at 37°C. Temperature was maintained using
a probe connected to the hotplate heater. After approximately
2 h of heating the model, TA (Kenalog R©, 4.0 mg in 100 :L)
was injected into the posterior segment of the model. Sampling
was accomplished daily by replacing the vial used to collect the
outflow from the anterior cavity. Samples were stored at 4°C
and then analyzed by HPLC (254 nm).
Quantification of Drug Release
The Bradford assay was used to determine protein concentra-
tion. Samples and standards (40 :L) were evaluated in trip-
licate using 96-well plates and mixed with Bradford Ultra
reagent (110 :L). Plates were incubated for 10 min at room
temperature and absorbance at 590 nm was measured using
a plate reader. The calibration curve (R2 value of 0.99) was
made using a solution of antibody (100 :g/mL) that was seri-
ally diluted (PBS, pH 7.4) to 10 :g/mL. Average measurements
for blank (0 :g/mL of antibody) were subtracted from stan-
dards and unknown samples. The concentrations of unknown
samples were estimated based on the standard curve. Samples
from each time point was evaluated in triplicate (n = 3) and the
mean and standard deviation were determined.
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Table 2. Summary of PK-Eye Prototype Development
Ports
Prototype In Out Vitreous (mL) Design Information Observations During Validation
A 1 1 5.6 A spherical globe made of
polyacrylate plastic
The volume was too large
compared with the human eye
B 2 1 4.2 Volume was adjusted to match
the average value reported in
human eyes
Cavity lacked spherical shape
C 2 4 4.2 Incorporation of anterior (0.2
mL) and posterior cavities
(4.2 mL)
Could not maintain a gel to
water interface between
posterior and anterior cavities
D 2 10 4.2 Fit cavity separating membrane
and increase outlet ports
Unequal and insufficient flow in
each port observed
E 2 4 4.2 Reduce the number of outlet
ports
Input port diameters too large
and too far away from the
cavity separating membrane
F 4 4 4.2 Move input ports to replicate
ciliary body location and flow
Inadequate and inconsistent
flow from each outlet port
G 4 1 4.2 Incorporation of new outlet port
in the anterior cavity
Too difficult to maintain an
accurate flow rate using four
inlet ports
H 1 1 4.2 One inlet to replicate ciliary
body flow
Much more practical to use than
with two inlet ports
The prototype that was used for these studies reported herein is H.
The concentration of TA (Kenalog R©) was determined by
HPLC with UV detection (254 nm) using methanol–water
(70:30, v/v) as the mobile phase. A retention time of approx-
imately 3.7 min was observed. The injection volume was 10 :L
with a flow rate of 1.0 mL/min and a run time of 10 min. The
calibration curve (R2 value of 0.97) was made starting with a
TA suspension (1 mg/mL) that was serially diluted using PBS
to 0.39 :g/mL.
Data Analysis
All results are presented as the mean and standard devia-
tion, and data were plotted using OriginPro. Half-lives (t1/2)
was calculated according to the best fitting model in Origin-
Pro. First-order kinetic rate constants (k) were derived from
the monoexponential curve and half-lives were calculated us-
ing the equation: 0.693/k. The rate constants (k) of zero-order
release profiles were calculated as concentration–time and
half-lives were calculated from initial concentration [A] using
[A]/2k.
RESULTS AND DISCUSSION
Dye Experiments to Illustrate Flow Properties of the Model
Dye studies were conducted to illustrate the need for flow and
compartmentalization of themodel.With the aqueous inlet flow
set at 2.0 :L/min, Coomassie blue dye was injected (100 :L,
1.2mM) into the anterior cavity (Fig. 2). The amount of dye used
was in large excess to what can be administered in an in vivo
experiment by either injection or the use of eye drops. The dye
cleared through the outlet port with only a trace amount being
observed to migrate into the posterior cavity at about 24 h after
injection (Fig. 2). In a second experiment, the dye was injected
into the posterior cavity. With aqueous inflow (2.0 :L/min), the
dye cleared from the posterior cavity into the anterior cavity
Figure 2. Injection of coomassie blue dye (100 :L, 1.2 mM) into anterior cavity of the model. The aqueous inflow into the posterior cavity was
2.0 :L/min. Only a trace amount of the dye can be seen to migrate into the posterior cavity (slight blue colouration in the posterior cavity at
24 h) as the dye clears from the anterior cavity.
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Figure 3. Injection of coomassie blue dye (100 :L, 1.2 mM) into the posterior cavity was monitored over time with (top panel) and without
(bottom panel) aqueous flow. The liquid in the model was PBS (pH 7.4). Dye does not pass into the anterior cavity or clear from the model unless
there is an aqueous inflow.
and then through the outlet port of the model (Fig. 3, upper
panel). When there was no flow (Fig. 3, lower panel), the dye
remained concentrated only in the posterior cavity.
These dye experiments broadly mimic mass transfer in the
eye that is caused by aqueous flow. When a drug is in the anter-
ior chamber, very little of it will pass into the posterior cav-
ity because of the aqueous outflow. And if a drug is in the
posterior cavity, flow is necessary for the drug to clear ante-
riorly via aqueous outflow. It was conspicuous that the dye did
not migrate between the two compartments unless flow was
induced (Figs. 2 and 3), so the visking membrane did offer bar-
rier properties to the dye. Coomassie blue has a relatively large
molecular weight (825 g/mol) and is partially soluble in wa-
ter because of its hydrophobic nature. The visking membrane
is made from reconstituted cellulose. Water is thought to swell
the membrane creating a hydrophilic barrier layer that can act
to inhibit the diffusion rate of hydrophobic molecules through
the membrane.58,59
In addition to in vitro permeation models,26,29 other in vitro
models have been described for the preclinical development
of IVT ophthalmic preparations.45,60–63 For example, the dis-
solution of poorly soluble drugs and extended-release tablets62
were evaluated using a USP4 dissolution apparatus with a flow
through of 1.5 mL/min in a chamber of 8–19 mL.64 Aspects of
drug distribution in the vitreous have been evaluated using a
model for saccades (i.e., eye movements), which can influence
drug distribution in the vitreous.65 This single compartment,
nonflow model was used to evaluate dye distribution in gly-
cerol and polyacrylamide gels as vitreous substitutes.66 These
in vitromodels do not mimic the human eye in terms of its com-
partmentalization, scale, or mass transfer properties because
of aqueous flow.
Computational modeling of the eye has also been used to
evaluate drug distribution within the vitreous of animals and
humans18,67–74 after injection or release by implants,75,76 and
to develop vitreous diffusion IVIVCs.77,78 The need to under-
stand how a drug is distributed within the vitreous to ac-
cess the retina has been a key driver for many of the stud-
ies focused on drug distribution within the posterior segment.
However, knowledge of vitreous distribution can only be com-
plete by first determining the residence time of a drug within
the vitreous. Any preclinical candidate designed for prolonged
action in the posterior cavity must be able to achieve ex-
tended PK properties in the presence of intraocular aqueous
flow.
Preincubation of the Model with Albumin
There was a concern that a protein undergoing evaluation
would adversely adsorb onto the internal plastic surfaces of the
model. The model was preincubated with a 0.1% albumin solu-
tion, and then with the inflow set at 2.0 :L/min, bevacizumab
was injected (1.25 mg in 50 :L) into the posterior cavity of the
model.
This experiment was conducted using PBS in the model to
allow rapid and complete distribution of bevacizumab through-
out the posterior cavity. The use of PBS in the posterior cavity
also acted to mimic the reduced viscosity of the vitreous after
a vitrectomy. The viscoelastic properties of the vitreous are in-
completely understood15,34,79 and there are many differences in
the composition and microstructure of the vitreous.24,30,36–38 As
a large molecule, the diffusion of a protein will be faster80 and
will clear more rapidly from a vitrectomized eye.28,81 It was also
thought that faster and probably more complete antibody dif-
fusion would occur in a low viscous solution that would make
it easier to observe its propensity to adsorb onto the plastic
surface.
The observed residence time of bevacizumab from the model
after preincubation with albumin followed first-order kinetics
andwas 1.5± 0.3 days (Fig. 4a).When themodel was not coated
with albumin, the bevacizumab clearance half-life was 1.2± 0.1
days (Fig. 4b). Although this was not significantly different with
the clearance half-life when the model was preincubated with
albumin, there appeared a less discernable peak concentration,
Awwad et al., JOURNAL OF PHARMACEUTICAL SCIENCES 104:3330–3342, 2015 DOI 10.1002/jps.24480
RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology 3335
Figure 4. Release profile of bevacizumab (1.25 mg) using PBS in the vitreal cavity. Half-life values were (a) 1.5 ± 0.3 days when the model
was preincubated with 0.1% albumin and (b) 1.2 ± 0.1 days without albumin preincubation. The concentration profile for the uncoated model
appeared not to have a distinct peak and early time points in the cumulative release profile were consistent with some delay of antibody outflow.
These observations suggest that bevacizumab may have interacted with the plastic surface of the uncoated model in phosphate buffer solution.
Each time point is shown as mean and standard deviation from three different experiments.
which suggests the bevacizumab reversibly adsorbed onto the
plastic surface of the uncoated model. The presence of a peak
concentration is characteristic for an intraocular injection73 and
was more evident when bevacizumab clearance was measured
in the albumin-coated model (Fig. 4a). If the model is fabricated
from plastic and PBS is used in the posterior cavity, consider-
ation should be made to preincubate with albumin or another
blocking protein prior to evaluating a candidate therapeutic
protein.
Bevacizumab is a monoclonal antibody that is widely used
as an unlicensed, butmore cost-effective anti-VEGFmedicine3,4
that is considered to be clinically equivalent to ranibizumab for
the treatment of some indications.82,83 It was encouraging that
the half-life of 1.5 ± 0.3 days from the albumin-coated model
(Fig. 4a) is comparable to the half-life of bevacizumab at the
same dose in vitrectomized monkey eyes (1.5 ± 0.6 days; n =
6).84 There is a report that the half-life of bevacizumab at a 1.25-
mg dose from a victrectomized human eye of a single patient
was 0.7 days.85 In nonvitrectomized human eyes at this dose,
the half-life of bevacizumab has mean values ranging from 4.9
to 10 days.81,85–88 In contrast, the half-life of bevacizumab at
this dose is 2.8 ± 0.6 days (n = 3)89 in normal monkey eyes that
have an intact vitreous. Although less human data exists for
the clearance of bevacizumab in vitrectomized eyes, clearance
is expected to be faster than in nonvitrectomized eyes. There
is also a significant variation in the half-lives for nonvictrec-
tomized human patients, so the monkey and human data are
also significantly different. On the basis of the more complete
monkey data, the model could be used to estimate the vitrec-
tomized clearance times by using PBS in the vitreous cavity. It
is thought this would provide the fastest clearance time possi-
ble for a given preclinical formulation.
Clearance Profile of Ranibizumab Using Simulated Vitreous Fluid
Protein therapeutics will diffuse more slowly in vitreous fluid,
which is generally more viscous than PBS. A simulated vitre-
ous liquid was then used in the posterior cavity of the model.
Reduced diffusion will prolong the time it takes for the protein
to clear from the vitreous cavity. Simulated biological fluids are
widely used to mimic aspects of an endogenous fluid during
preclinical research.32,90 Vitreous substitutes are also widely
used, both clinically and for preclinical research.91,92 We used a
simulated vitreous fluid prepared from HA and agar56 that had
a dynamic viscosity of approximately 0.6 Pa·s, which is com-
parable to human vitreous (0.5 Pa·s).93 Initial experiments
established that none of the components of the simulated vit-
reous diffused into the anterior cavity of the model and that
the simulated vitreous maintained its viscosity over time (2–
3 weeks). No substrates were observed in the outflow unless
ranibizumab was first injected.
Ranibizumab was then injected into the vitreous cavity of
the model using the usual clinical dose (0.5 mg, 50 :L). The
ranibizumab clearance half-life in the model followed first-
order kinetics and was 8.1 ± 3.1 days (Fig. 5a), which is similar
to the half-life in humans at this dose (7.294 and 9.095 days).
Using simulated vitreous provides the means to estimate the
time needed for a therapeutic protein to clear via the aqueous
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Figure 5. Release profiles and outflow concentrations of ranibizumab (0.5 mg) after injection into the posterior cavity. The half-life values were
(a) 1.5 ± 0.6 days with PBS and (b) 8.0 ± 3.1 days with simulated vitreous in the posterior cavity. The release profile from simulated vitreous
was similar to that observed for humans. Each time point is shown as mean and standard deviation from three different experiments.
outflow pathway from a human eye. When PBS was used in
the posterior cavity, the clearance half-life of ranibizumab was
1.5 ± 0.6 days (Fig. 5b). This was comparable to bevacizumab
(Fig. 4a). When the model was pre-incubated with albumin and
then rinsed, no protein was observed from the outflow. Protein
was only observed when the sample, i.e. ranibizumab, was in-
jected into the posterior cavity of the model.
The visking membrane had a molecular weight cut off value
of 12–14 kDa. This refers to the smallest number average
molecularweight of a globularmacromolecule thatwill be about
90% retained when dialyzed overnight,96 although there are no
strict specification standards.55 It was anticipated that with ex-
periments lasting several days to weeks, that passage through
the membrane of small amounts of molecules with larger mol-
ecular weight would be possible. This is what was observed for
both the ranibizumab and bevacizumab experiments (Figs. 4
and 5). It was also necessary for the membrane to ensure the
simulated vitreous solution remained in the posterior cavity
without allowing the gelled material to pass into the anterior
cavity. The simulated vitreous should be made using very high-
molecular-weight gelling components that form a stable viscous
solution.
As a Fab, ranibizumab (48 kDa) is about 1/3 the molecu-
lar weight of bevacizumab (150 kDa), which is a full mono-
clonal antibody. In humans, these molecules display compar-
able mean half-lives with a similar therapeutic effect.21,86,94
The half-lives for ranbizumab span from about 7.2 to 9.0 days
and for bevacizumab, the range is about 6.7–10.0 days.81,85–88
As mentioned, these half-lives can be reduced because of med-
ical conditions such as vitrectomy and retinal detachment.97
The usual clinical dose for ranibizumab (0.5 mg) is about 20%
more than bevacizumab (1.25 mg) on a molar basis. Of the
other biologics registered for ophthalmic use by IVT injection,1
there is no reported human half-life data for the Fc fragment
fusion (alfibercept, 115 kDa),1,81 but the PEGylated-aptamer
(Pegaptanib, 50 kDa) displays a mean half-life of about 7–
8 days for a IVT dose of 0.3 mg as determined by plasma
measurements.98 Although the half-life of Pegaptanib is essen-
tially the same as ranibizumab, its dose is about 60% of that
is used for ranibizumab on a molar basis. Increasing the dose
of Pegaptanib by 10 times of the US FDA-approved dose to 3.0
mg only increases the half-life to about 10 (±4) days.99,100
These observations suggest that there is probably a
“molecular weight threshold” after which most proteins and
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macromolecular drugs will display comparable half-lives in the
posterior cavity due to clearance by the aqueous outflow path-
way. New strategies are being developed to increase the vitre-
ous resident times of macromolecular drugs.7,10,19,34,101–103 Some
of these strategiesmay employ the use of implants (for example)
where a release or dissolution step is required prior to clear-
ance of the protein therapeutic. It is for these new strategies
that we believe our model will find real utility in preclinical
research. The strategy to increase the dose of a molecule as
a means to increase its “therapeutic tail,” which is used with
aflibercept, can also be evaluated in a realistic 2-compartment
outflow model such as the PK-Eye. As more stable protein ther-
apeutics are developed,much higher concentrated dosesmay be
possible where exploitation of the therapeutic tail is difficult to
evaluate in an animal model simply because of the generation
of ADAs.
The need during preclinical research to obtain reliable phar-
macokinetic information using animal models alone for pro-
tein therapeutics cannot be adequately met. The use of our
model will avoid the problems associated with ADAs.39–43
The model also avoids the need to consider the anatomical
differences28,33–35 that exist between animal and human eyes.
For example, globe sizes of the rabbit (New Zealand white) and
monkey (cynomolgus) are similar, but the relative sizes of the
anterior chamber and lens of the rabbit are much larger than
the monkey.33 The rabbit vitreous is about 50% the size of the
monkey vitreous (and about 30%–40% that of the human vit-
reous). But the aqueous flow of the rabbit (2.0 L/min104) and
monkey (2.8 L/min105) are similar to that of the human. Al-
though clearance of ranibizumab will be primarily driven by its
diffusion through the vitreous,28 its clearance should be faster
in the rabbit (less vitreous, larger anterior cavity, shorter diffu-
sion path). However, the half-life of ranibizumab (0.5 mg) from
the rabbit and monkey are about the same, being about 2.8–2.9
days22,106,107 and about 3 days,35 respectively. Even though the
monkey eye is more similar to the human eye than is the rabbit
eye,33 the half-life for IVT-injected ranibizumab (0.5 mg) from
the monkey is much less than that observed in humans (7.294
and 9.095 days).
Although three of the four clinically used macromolecular
therapeutics broadly display similar mean half-lives in hu-
mans, there is still range of clearance times that is indica-
tive of how intraocular pharmacokinetics can vary in human
eyes that are being treated. This variation may be because of
how the IVT injection procedure is conducted,28,108,109 but more
often there are complicating medical conditions86,110,111 in pa-
tients that require IVT injections that could facilitate greater
RCS uptake of nonpermeable molecules. There are also vari-
ations in vitreous composition37 that can influence flow in the
posterior chamber of human eyes68,112 where aqueous outflow
through the retina may increase.30 Variations in the vitreous
occur because of (1) age (i.e., liquefaction),24,28,38 (2) whether
a vitrectomy has been performed, and (3) due to the nature
of the medical condition afflicting the eye. For example, small
breaks in the inner-limiting membrane (ILM)113,114 can cause
retinal uptake of non-RCS permeable molecules such as ther-
apeutic proteins.21,87,110,111,115 The intact ILM that is between
the vitreous and retina can act as a barrier for macromolecules
to the retina.7,34 The pharmacokinetics of antibodies can fur-
ther vary because of the presence of Fc receptors in the retinal
tissue.115–117 Although some posterior aqueous outflow occurs
through the retina, the relative amount may be higher in an-
imal models than in humans17 and radiolabelled ranibizumab
can be detected within the retina of the rabbit.118 However,
quantifying the total dose that may clear through the retina119
or extrapolating data for retinal uptake from an animal model
after IVT administration is not yet possible. The use of the
model with PBS in the vitreous cavity can provide data for
the fastest vitreous clearance time to be expected for a pre-
clinical candidate. If considered along with the clearance times
obtained with simulated vitreous, it will be possible to obtain
minimum and maximum estimates for posterior cavity clear-
ance times very early in preclinical research.
It is not possible with in vivo animal studies to mimic the
wide range of conditions encountered in human eyes that may
cause pharmacokinetic variation. For example, ranibizumab
(and bevacizumab) clearance from vitrectomized rabbit eyes
is about the same107 or at best slightly reduced compared with
nonvitrectomized rabbit eyes.106 This may be because of the
large rabbit lens making it difficult to remove a high enough
proportion of the vitreous.107,109 As longer-lasting preparations
are developed, differences in human ocular pharmacokinetics
will persist to obscure clinical outcomes. It is important in pre-
clinical research to obtain robust PK data based on the aque-
ous outflow pathway because it appears to change less than
RCS pathways for many of the intraocular diseases that re-
quire treatment by IVT injections. It is possible with our model
to obtain good estimates of the upper limit for clearance early
in preclinical studies. The many medical conditions that con-
tribute to accelerate clearance times can then be accounted
for to estimate the different clearance times that might occur
clinically.120 Furthermore, as longer-lasting therapeutic protein
preparations are developed, the use of our outflow model will
allow for easy sampling to evaluate protein stability that will be
important for preparations designed to last 2–3 months inside
the vitreous cavity.
Clearance Profile of TA Suspension (Kenalog R©)
The clinical use of steroid implants (e.g., Ozurdex R© and
Iluvien R©) that release drug over several months into the vitre-
ous are examples of IVT implants19 that may become increas-
ingly more common in the clinic.19,24,34,102,103,121–123 Many cur-
rent implants utilize poorly soluble steroids124 so the nonsink
conditions of the posterior cavity can be exploited to prolong
the vitreous resident time. Steroids tend to be lipophilic and
permeable, and so a significant amount of material solubilized
in the vitreous would be expected to clear by both RCS and
anterior outflow pathways. Once a permeable, low-molecular-
weight molecule is solubilized in the vitreous, clearance would
be expected to be relatively quick.18,24,27,28 For example, the half-
life of intravitreally injected dexamethasone phosphate, which
is water soluble, is 3.48 h.27
Prior to the development of implants, the IVT injection of a
suspension of a poorly soluble drug such as TA (Kenalog R©)125,126
was the best way to clinically prolong the presence of a drug
in the vitreous cavity. TA solubility is in the range of approx-
imately 21–30 :g/mL depending on solution media and tem-
perature (25°C–37°C).127,128 Kenalog R© is the most commonly
used TA preparation and has long been used for ophthalmic
conditions125,126,129; however, there are other, preservative-free,
TA formulations available that include Triesence R© (Alcon) and
Trivaris R© (Allergan).129
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Figure 6. Release profiles and outflow concentrations of TA (Kenalog R©, 4.0 mg) injected into the posterior cavity at 37°C. The half-life values
were (a) 26.1 ± 0.8 days with PBS and (b) 27.8 ± 3.4 days with simulated vitreous in the posterior cavity. The solubility limited concentration
profile was constant and about the same for PBS and the simulated vitreous. This profile is as expected for a dissolving solid or eluting implant
in the vitreous cavity, which acts a single nonsink compartment with liquid out flow. Each time point is shown as mean and standard deviation
from three different experiments.
Triamcinolone acetonide (Kenalog R©, 4.0 mg in 100 :L) was
injected into the posterior cavity of the model, which was
heated to 37°C. The dissolution rate of the TA suspension is
solubility controlled in the total liquid volume of the model
and a near constant-release concentration (25–30 :g/mL) in
both PBS and simulated vitreous was observed (Fig. 6). The
clearance half-life of TA from the model was in the range of
26–28 days.
The mean half-life in humans for the IVT administration
of TA at the same dose spans 15.4130–18.6 days.131 This clear-
ance time is faster than what was observed in the model be-
cause of contributing clearance through RCS pathways. RCS
permeable molecules once in solution will clear through both
RCS and anterior outflow pathways. Although active trans-
port by the RCS can be significant for some molecules,72 our
model will provide an estimate of the upper time period for
clearance. The model can be used to estimate drug release
from implants or the dissolution of suspensions as a first step
in their clearance. This will often be the rate-limiting step
that defines the overall clearance time of a candidate prepa-
ration. Once the active is in solution, the model has the ca-
pacity to provide a good estimate of clearance by the anterior
outflow route. As for other preparations designed for differ-
ent modes of administration (e.g., oral, pulmonary), this infor-
mation can be used with an in vitro26 or computational18,29–31
permeability model to develop IVIVCs.49,52,53 There is intense
effort to develop implants and other long-acting preparations
from proteins, peptides and nucleotides,7,10,19,34,101,103 and pos-
sibly other low-molecular-weight substances (e.g., the antiviral
agent, Foscarnet18) that do not clear to a great extent by the
RCS. In these cases, the preclinical use of our model would be
expected to provide good estimates of useful clearance times.
CONCLUSIONS
The PK-Eye is a novel pharmacokinetic in vitromodel designed
for use during preclinical studies to accelerate the development
of longer-lasting therapeutic dosage forms that are needed to
treat chronic blinding conditions. Our low-cost, two compart-
ment in vitro model is scaled to the human eye and the model
mimics the mass transfer characteristics caused by anterior
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aqueous outflow. Therapeutic proteins are large hydrophilic
molecules, so they are expected to clear primarily by aque-
ous outflow pathways. The formation of ADAs in animals in
response to human therapeutic proteins and the anatomical
differences in animal models make it difficult to correlate clear-
ance profiles with that expected from human eyes. Animal stud-
ies also tend to be expensive with a large degree of variation
because of the range of experimental protocols that are fol-
lowed. Ethically, animal experimentation should be minimized
when possible, especially when providing limited information.
Dye validation studies and clearance studies utilizing the
model in different configurations (e.g., use of either PBS or
simulated vitreous) indicate that relevant clearance profiles
can be obtained using the model for both proteins and poorly
soluble drugs injected as a suspension, or potentially formu-
lated as an implant. Release of an active from an implant or its
dissolution from a particulate or suspension will often be the
rate-limiting step that defines the overall clearance time of a
candidate preparation.
Obtaining PK data for molecules that clear predominantly
by the aqueous outflow pathway is important because char-
acteristics of aqueous outflow appear to change less than the
permeability properties of the tissues at the back of eye. As
longer-lasting preparations are developed, differences in hu-
man ocular pharmacokinetics will persist to obscure clinical
outcomes. It is possible with our model to obtain good estimates
of the maximum and minimum vitreous clearance times early
in preclinical studies. This will allow faster optimization cycles
during early preclinical studies while avoiding the needless use
of animal models until absolutely necessary. Our model can be
used with other in vitro or computational permeability mod-
els to develop IVIVCs that include RCS clearance pathways.
This is analogous to strategies that are used to develop new
dosage forms for oral and pulmonary administration. Our in
vitromodel can easily be used to evaluate protein function and
stability. This is difficult to accomplish using animal models
and is especially important for dosage forms that have longer
clearance times that could extend over a 2–3-month period.
Our studies show the PK-Eye model has many of the features
needed to become a practical in vitro model with the capacity
to contribute to research efforts focused on the development of
new ophthalmic medicines.
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